JP6625045B2 - 相同組換え欠損を評価するための方法および材料 - Google Patents

相同組換え欠損を評価するための方法および材料

Info

Publication number
JP6625045B2
JP6625045B2 JP2016506657A JP2016506657A JP6625045B2 JP 6625045 B2 JP6625045 B2 JP 6625045B2 JP 2016506657 A JP2016506657 A JP 2016506657A JP 2016506657 A JP2016506657 A JP 2016506657A JP 6625045 B2 JP6625045 B2 JP 6625045B2
Authority
JP
Japan
Prior art keywords
region
indicator
pairs
loh
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016506657A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016523511A (ja
JP2016523511A5 (cg-RX-API-DMAC10.html
Inventor
ビクター アブケビック
ビクター アブケビック
キルスティン ティムズ
キルスティン ティムズ
アレクサンダー グティン
アレクサンダー グティン
Original Assignee
ミリアド・ジェネティックス・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51659359&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6625045(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ミリアド・ジェネティックス・インコーポレイテッド filed Critical ミリアド・ジェネティックス・インコーポレイテッド
Publication of JP2016523511A publication Critical patent/JP2016523511A/ja
Publication of JP2016523511A5 publication Critical patent/JP2016523511A5/ja
Priority to JP2019085187A priority Critical patent/JP7522539B2/ja
Application granted granted Critical
Publication of JP6625045B2 publication Critical patent/JP6625045B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6858—Allele-specific amplification
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
JP2016506657A 2013-04-05 2014-04-04 相同組換え欠損を評価するための方法および材料 Active JP6625045B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019085187A JP7522539B2 (ja) 2013-04-05 2019-04-26 相同組換え欠損を評価するための方法および材料

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361809105P 2013-04-05 2013-04-05
US61/809,105 2013-04-05
US201361913762P 2013-12-09 2013-12-09
US61/913,762 2013-12-09
PCT/US2014/033014 WO2014165785A2 (en) 2013-04-05 2014-04-04 Methods and materials for assessing homologous recombination deficiency

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019085187A Division JP7522539B2 (ja) 2013-04-05 2019-04-26 相同組換え欠損を評価するための方法および材料

Publications (3)

Publication Number Publication Date
JP2016523511A JP2016523511A (ja) 2016-08-12
JP2016523511A5 JP2016523511A5 (cg-RX-API-DMAC10.html) 2017-03-16
JP6625045B2 true JP6625045B2 (ja) 2019-12-25

Family

ID=51659359

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2016506657A Active JP6625045B2 (ja) 2013-04-05 2014-04-04 相同組換え欠損を評価するための方法および材料
JP2019085187A Active JP7522539B2 (ja) 2013-04-05 2019-04-26 相同組換え欠損を評価するための方法および材料
JP2020194936A Active JP7522643B2 (ja) 2013-04-05 2020-11-25 相同組換え欠損を評価するための方法および材料
JP2022169085A Active JP7641938B2 (ja) 2013-04-05 2022-10-21 相同組換え欠損を評価するための方法および材料
JP2025027653A Pending JP2025090619A (ja) 2013-04-05 2025-02-25 相同組換え欠損を評価するための方法および材料

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2019085187A Active JP7522539B2 (ja) 2013-04-05 2019-04-26 相同組換え欠損を評価するための方法および材料
JP2020194936A Active JP7522643B2 (ja) 2013-04-05 2020-11-25 相同組換え欠損を評価するための方法および材料
JP2022169085A Active JP7641938B2 (ja) 2013-04-05 2022-10-21 相同組換え欠損を評価するための方法および材料
JP2025027653A Pending JP2025090619A (ja) 2013-04-05 2025-02-25 相同組換え欠損を評価するための方法および材料

Country Status (9)

Country Link
US (4) US20140363521A1 (cg-RX-API-DMAC10.html)
EP (2) EP3693475A1 (cg-RX-API-DMAC10.html)
JP (5) JP6625045B2 (cg-RX-API-DMAC10.html)
AU (3) AU2014248007B2 (cg-RX-API-DMAC10.html)
CA (1) CA2908745C (cg-RX-API-DMAC10.html)
DK (1) DK2981624T3 (cg-RX-API-DMAC10.html)
ES (1) ES2777228T3 (cg-RX-API-DMAC10.html)
PT (1) PT2981624T (cg-RX-API-DMAC10.html)
WO (1) WO2014165785A2 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019165731A (ja) * 2013-04-05 2019-10-03 ミリアド・ジェネティックス・インコーポレイテッド 相同組換え欠損を評価するための方法および材料

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2704303T3 (es) 2010-08-24 2019-03-15 Dana Farber Cancer Inst Inc Procedimientos para la predicción de una respuesta contra el cáncer
EP3225697A3 (en) 2010-12-30 2017-11-22 Foundation Medicine, Inc. Optimization of multigene analysis of tumor samples
ES2768344T3 (es) 2011-06-17 2020-06-22 Myriad Genetics Inc Métodos y materiales para evaluar el desequilibrio alélico
JP6325453B2 (ja) 2011-12-21 2018-05-16 ミリアド・ジェネティックス・インコーポレイテッド ヘテロ接合性の消失（ｌｏｓｓｏｆｈｅｔｅｒｏｚｙｇｏｓｉｔｙ）を評価するための方法および材料
ES2687024T3 (es) 2012-02-23 2018-10-23 Children's Medical Center Corporation Procedimientos para predecir la respuesta contra el cáncer
CA2867434C (en) 2012-06-07 2021-10-12 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
CA2931181C (en) 2013-12-09 2023-01-24 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
US10545151B2 (en) 2014-02-21 2020-01-28 Epic Sciences, Inc. Methods for analyzing rare circulating cells
DK3686288T3 (da) 2014-08-15 2023-05-22 Myriad Genetics Inc Fremgangsmåder og materialer til analyse af homolog rekombinationsdeficiens
ES2989276T3 (es) * 2014-12-05 2024-11-25 Found Medicine Inc Análisis multigénico de muestras tumorales
US20160160294A1 (en) * 2014-12-08 2016-06-09 Tesaro Methods and materials for predicting response to niraparib
US20180148792A1 (en) 2015-05-19 2018-05-31 T.S. Sridhar Method for Identification of a Deficient BRCA1 Function
CN115341033A (zh) * 2015-11-03 2022-11-15 艾匹克科学公司 一种表征疾病异质性的方法
WO2017106365A1 (en) * 2015-12-14 2017-06-22 Myriad Genetics, Inc. Methods for measuring mutation load
US20190025312A1 (en) * 2016-01-06 2019-01-24 Epic Sciences, Inc. Single cell genomic profiling of circulating tumor cells (ctcs) in metastatic disease to characterize disease heterogeneity
WO2017165270A1 (en) * 2016-03-21 2017-09-28 Myriad Genetics, Inc. Homologous recombination deficiency to predict neoadjuvant chemotherapy necessity in bladder cancer
WO2017178509A1 (en) 2016-04-12 2017-10-19 Xentech Methods for predicting sensibility to treatment with parp inhibitors in cancerous patients
GB2555765A (en) 2016-05-01 2018-05-16 Genome Res Ltd Method of detecting a mutational signature in a sample
WO2017191074A1 (en) * 2016-05-01 2017-11-09 Genome Research Limited Method of characterising a dna sample
US12062416B2 (en) 2016-05-01 2024-08-13 Genome Research Limited Method of characterizing a DNA sample
HRP20240136T1 (hr) 2016-06-29 2024-04-12 Tesaro, Inc. Metode liječenja raka jajnika
KR20210035167A (ko) 2018-06-11 2021-03-31 파운데이션 메디신 인코포레이티드 게놈 변경을 평가하기 위한 조성물 및 방법
JPWO2020137076A1 (ja) * 2018-12-28 2021-11-11 国立大学法人 東京大学 Ｐａｒｐ阻害剤に対する癌の感受性の予測方法および相同組換修復不全を有する癌の検出方法
US10975445B2 (en) 2019-02-12 2021-04-13 Tempus Labs, Inc. Integrated machine-learning framework to estimate homologous recombination deficiency
WO2021119311A1 (en) 2019-12-10 2021-06-17 Tempus Labs, Inc. Systems and methods for predicting homologous recombination deficiency status of a specimen
CN114829624A (zh) * 2019-12-16 2022-07-29 安捷伦科技有限公司 基因组瘢痕测定和相关方法
EP3945525A1 (en) 2020-07-27 2022-02-02 Sophia Genetics S.A. Methods for identifying chromosomal spatial instability such as homologous repair deficiency in low coverage next-generation sequencing data
CN111883211B (zh) * 2020-08-07 2021-04-23 张哲� 一种表征hrd同源重组修复缺陷的基因瘢痕及鉴定方法
CN111676277B (zh) * 2020-08-12 2020-12-15 臻和(北京)生物科技有限公司 一种基于二代测序技术测定基因组不稳定的方法及试剂盒
CN112164420B (zh) 2020-09-07 2021-07-20 厦门艾德生物医药科技股份有限公司 一种基因组瘢痕模型的建立方法
CN112410423B (zh) * 2020-11-03 2021-08-13 南京世和基因生物技术股份有限公司 同源重组缺失的标志物、检测方法以及检测系统
JP7585015B2 (ja) 2020-12-04 2024-11-18 株式会社東芝 核酸構築物のセット、キット、検出方法及び薬剤効果予測方法
US20240052423A1 (en) * 2020-12-07 2024-02-15 Pfizer Inc. Methods of identifying a tumor that is sensitive to treatment with talazoparib and methods of treatment thereof
CN114096681B (zh) * 2021-01-10 2024-06-21 行动基因(智财)有限公司 同源重组缺失检测方法及其试剂组
BE1029144B1 (fr) 2021-02-25 2022-09-20 Oncodna Méthode de caracterisation d'une tumeur à l'aide d'un séquençage ciblé
CN112820351A (zh) * 2021-03-01 2021-05-18 江苏医联生物科技有限公司 检测肿瘤患者的突变和hrd评分指导用药的方法
AU2022299105A1 (en) * 2021-06-25 2024-01-04 Foundation Medicine, Inc. System and method of classifying homologous repair deficiency
CA3240150A1 (en) * 2021-12-08 2023-06-15 Alexander Gutin Methods and materials for assessing homologous recombination deficiency in breast cancer subtypes
KR102523938B1 (ko) * 2022-02-04 2023-04-19 가톨릭대학교 산학협력단 상동 재조합 결핍증 예측 모델의 모델링 방법
US20260139317A1 (en) 2022-10-19 2026-05-21 Vib Vzw Method of Determining Loss of Heterozygosity Status of a Tumor
EP4792336A1 (en) 2023-10-10 2026-08-19 Vib Vzw Method of detecting loss of heterozygosity status of a tumor
EP4791901A1 (en) 2023-10-10 2026-08-19 Vib Vzw Methods of determining response of a tumor to dna-damaging agents or to agents inhibiting or impairing dna repair

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU33730B (en) 1967-04-18 1978-02-28 Farmaceutici Italia Process for preparing a novel antibiotic substance and salts thereof
GB1432562A (en) 1972-04-10 1976-04-22 Rustenburg Platinum Mines Ltd Platinum co-ordination compounds
GB1432563A (en) 1972-04-10 1976-04-22 Rustenburg Platinum Mines Ltd Platinum- co-ordination compounds
ES444380A1 (es) 1976-01-16 1977-06-16 Gosalvez Mario Un procedimiento para preparar derivados metalicos antraci- clinicos.
US4950738A (en) 1984-09-13 1990-08-21 Cytogen Corporation Amine derivatives of anthracycline antibiotics
US5977082A (en) 1985-08-02 1999-11-02 Pharmacia & Upjohn Company Injectable ready-to-use solutions containing an antitumor anthracycline glycoside
US5177075A (en) 1988-08-19 1993-01-05 Warner-Lambert Company Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process
US5295944A (en) 1991-05-14 1994-03-22 Dana-Farber Cancer Institute Method for treating a tumor with ionizing radiation
ZA928771B (en) 1991-11-15 1993-09-08 Smithkline Beecham Corp Combination chemotherapy
GB9806324D0 (en) 1998-03-24 1998-05-20 Pharmacia & Upjohn Spa Antitumour synergetic composition
US6887996B2 (en) 2000-12-01 2005-05-03 Guilford Pharmaceuticals Inc. Compounds and their use
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
WO2005002508A2 (en) 2003-06-11 2005-01-13 Access Pharmaceuticals, Inc. Macromolecular platinum chelates
WO2005004805A2 (en) 2003-07-02 2005-01-20 Solux Corporation Thermally stable crystalline epirubicin hydrochloride and method of making the same
MXPA06000993A (es) 2003-07-25 2006-08-31 Cancer Rec Tech Ltd Inhbidores triciclicos de parp.
CA2535762A1 (en) 2003-08-13 2005-03-17 University Of South Florida Methods for inhibiting tumor cell proliferation
DE602006018299D1 (de) 2005-06-30 2010-12-30 Bionumerik Pharmaceuticals Inc Platinanaloga mit monoazolligand
KR100925337B1 (ko) * 2009-05-25 2009-11-09 주식회사 마크로젠 염색체 수 이상 검출을 통한 유방암 약물 반응성 예측
EP3327148B1 (en) 2010-06-18 2021-03-17 Myriad Genetics, Inc. Methods of predicting the status of brca1 and brca2 genes in a cancer cell
ES2704303T3 (es) * 2010-08-24 2019-03-15 Dana Farber Cancer Inst Inc Procedimientos para la predicción de una respuesta contra el cáncer
ES2687024T3 (es) * 2012-02-23 2018-10-23 Children's Medical Center Corporation Procedimientos para predecir la respuesta contra el cáncer
DK2981624T3 (da) * 2013-04-05 2020-03-02 Myriad Genetics Inc Fremgangsmåder til vurdering af homolog rekombinationsdeficiens og forudsigelse af respons på cancerbehandling

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019165731A (ja) * 2013-04-05 2019-10-03 ミリアド・ジェネティックス・インコーポレイテッド 相同組換え欠損を評価するための方法および材料

Also Published As

Publication number Publication date
JP2016523511A (ja) 2016-08-12
JP2021036903A (ja) 2021-03-11
EP3693475A1 (en) 2020-08-12
AU2020204028B2 (en) 2022-08-18
JP2025090619A (ja) 2025-06-17
AU2014248007A1 (en) 2015-10-15
ES2777228T3 (es) 2020-08-04
US20180030544A1 (en) 2018-02-01
AU2014248007B2 (en) 2020-03-26
JP7641938B2 (ja) 2025-03-07
US20210310079A1 (en) 2021-10-07
US20140363521A1 (en) 2014-12-11
DK2981624T3 (da) 2020-03-02
EP2981624B1 (en) 2019-12-18
PT2981624T (pt) 2020-03-23
JP7522643B2 (ja) 2024-07-25
CA2908745A1 (en) 2014-10-09
JP2023012488A (ja) 2023-01-25
WO2014165785A2 (en) 2014-10-09
NZ712663A (en) 2021-07-30
EP2981624A4 (en) 2016-11-30
CA2908745C (en) 2023-03-14
EP2981624A2 (en) 2016-02-10
AU2022211880B2 (en) 2025-05-29
JP7522539B2 (ja) 2024-07-25
AU2022211880A1 (en) 2022-09-01
AU2020204028A1 (en) 2020-07-09
US20250223655A1 (en) 2025-07-10
JP2019165731A (ja) 2019-10-03

Similar Documents

Publication Publication Date Title
JP7641938B2 (ja) 相同組換え欠損を評価するための方法および材料
JP7680995B2 (ja) 相同組換え欠損を評価するための方法および材料
WO2017165270A1 (en) Homologous recombination deficiency to predict neoadjuvant chemotherapy necessity in bladder cancer
TWI861616B (zh) 用於評估乳癌亞型中同源重組缺陷之方法及材料
HK40098329A (en) Methods and materials for assessing homologous recombination deficiency
HK40098329B (en) Methods and materials for assessing homologous recombination deficiency
NZ712663B2 (en) Methods and materials for assessing homologous recombination deficiency

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20160415

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160415

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170213

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20171221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180131

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180320

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180727

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190426

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20190514

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190731

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190806

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191108

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191126

R150 Certificate of patent or registration of utility model

Ref document number: 6625045

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250